TOULOUSE - ABIONYX Pharma (Paris: ABNX), (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces today its gross cash position at the end of the first half of 2020.

Gross cash position

ABIONYX Pharma's activities being dedicated to the discovery and development of innovative therapies to improve the lives of patients, the Company did not generate any revenue in the first semester of 2020. Cash and cash equivalents amounted to EUR8.8 million at June 30th, 2020.

Significant events and outlook

Given the ATUn in an ultra-rare kidney disease and the current context of healthcare systems impacted by Covid-19, the company is still awaiting clinical data that may influence the determination of the new strategic plan.

Annual General Meeting of 29 May 2020: changes to come following an error on certain resolutions

A material error was made in the first three resolutions presented during the last General Meeting on May 29, 2020.

The financial statements filed and presented in the Universal Registration Document correspond to the latest version of the Company's financial statements, including the most recent amendments; they are presented as follows: the annual financial report shows a profit of EUR2,298,874.48 to replace the erroneous amount of EUR2,094,792.48; the consolidated financial statements show a profit of 1,849 KEUR replacing the erroneous amount of 1,823 KEUR; the allocation of the result of EUR2,298,874.48 to the retained earnings account will bring its balance to the debit amount of EUR163,629,843.66, replacing the announced amount of EUR163,833,925.66.

These adjustments will be put to the vote at the next General Assembly to be held.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.

Contact:

Louis-Victor Delouvrier

Tel: +33 (0)1 44 71 98 53

Email: abionyx@newcap.eu

(C) 2020 Electronic News Publishing, source ENP Newswire